DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $204,240 | -5.6% | 851 | -0.8% | 0.06% | -7.5% |
| Q1 2023 | $216,250 | -4.3% | 858 | +0.8% | 0.07% | -11.8% |
| Q4 2022 | $225,872 | +2.7% | 851 | 0.0% | 0.08% | -13.6% |
| Q3 2022 | $220,000 | -1.8% | 851 | -3.5% | 0.09% | +12.8% |
| Q2 2022 | $224,000 | -13.5% | 882 | 0.0% | 0.08% | 0.0% |
| Q1 2022 | $259,000 | -4.1% | 882 | +7.3% | 0.08% | -11.4% |
| Q4 2021 | $270,000 | +8.0% | 822 | 0.0% | 0.09% | +10.0% |
| Q3 2021 | $250,000 | +13.1% | 822 | 0.0% | 0.08% | 0.0% |
| Q2 2021 | $221,000 | +20.8% | 822 | 0.0% | 0.08% | +27.0% |
| Q4 2020 | $183,000 | +3.4% | 822 | 0.0% | 0.06% | -4.5% |
| Q3 2020 | $177,000 | +23.8% | 822 | +1.5% | 0.07% | +13.8% |
| Q2 2020 | $143,000 | +27.7% | 810 | 0.0% | 0.06% | +16.0% |
| Q1 2020 | $112,000 | -6.7% | 810 | +4.0% | 0.05% | +6.4% |
| Q4 2019 | $120,000 | +6.2% | 779 | 0.0% | 0.05% | 0.0% |
| Q3 2019 | $113,000 | +1.8% | 779 | 0.0% | 0.05% | -4.1% |
| Q2 2019 | $111,000 | +7.8% | 779 | 0.0% | 0.05% | +6.5% |
| Q1 2019 | $103,000 | +28.8% | 779 | 0.0% | 0.05% | +21.1% |
| Q4 2018 | $80,000 | +33.3% | 779 | +41.6% | 0.04% | +40.7% |
| Q3 2018 | $60,000 | +11.1% | 550 | 0.0% | 0.03% | +3.8% |
| Q2 2018 | $54,000 | 0.0% | 550 | 0.0% | 0.03% | -3.7% |
| Q1 2018 | $54,000 | +5.9% | 550 | 0.0% | 0.03% | -15.6% |
| Q4 2017 | $51,000 | +8.5% | 550 | 0.0% | 0.03% | +3.2% |
| Q3 2017 | $47,000 | +2.2% | 550 | 0.0% | 0.03% | -3.1% |
| Q2 2017 | $46,000 | -2.1% | 550 | 0.0% | 0.03% | -5.9% |
| Q1 2017 | $47,000 | -25.4% | 550 | -31.8% | 0.03% | -39.3% |
| Q4 2016 | $63,000 | +46.5% | 807 | +46.7% | 0.06% | +21.7% |
| Q3 2016 | $43,000 | -21.8% | 550 | 0.0% | 0.05% | -24.6% |
| Q2 2016 | $55,000 | +5.8% | 550 | 0.0% | 0.06% | +29.8% |
| Q1 2016 | $52,000 | -16.1% | 550 | -18.5% | 0.05% | -6.0% |
| Q4 2015 | $62,000 | +8.8% | 675 | 0.0% | 0.05% | -29.6% |
| Q3 2015 | $57,000 | +21.3% | 675 | +22.7% | 0.07% | +39.2% |
| Q2 2015 | $47,000 | 0.0% | 550 | 0.0% | 0.05% | +6.2% |
| Q1 2015 | $47,000 | 0.0% | 550 | 0.0% | 0.05% | -4.0% |
| Q4 2014 | $47,000 | – | 550 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |